Pfizer Successfully Implements Endosafe® Endotoxin Testing Platforms

Apr 21 2014

Over the last 3 years, Pfizer has assessed the Endosafe® rapid test methods on dozens of applications and gathered extensive data to support comparability to USP<85> and PharmEur 2.6.14 Bacterial Endotoxin.

This poster, which was presented by Pfizer at the 2014 PDA Annual Meeting, provides a summary of the methodology, Endosafe® platform, collected data to support compatibility to traditional methods, examples of implementation and the operational benefits realized.

Summary of Evaluation and Benefits:

  • 47,000+ water and buffer samples tested, by 19 different users, demonstrated the assay performs as designed, results distributed across compendial acceptance of 50% to 200% spike recovery
  • Endosafe platform system aligned with USP<85> and PharmEur 2.6.14
  • Reduced operator error, cost/test, training, metrology, reagent overhead/control and technician test time
  • Reduction of investigations (~$1,800/investigations)
  • Moved upwards of 60% of testing from Lab to Floor
  • Pfizer global implementation: 69 PTS™ units and 20+ MCS™ units

Contact us today to learn how you can improve lab efficiencies and decrease testing times by transitioning from a traditional methods to the Endosafe®-PTS™.

Implementation of the Endosafe® Rapid Endotoxin Testing Platform at Pfizer

Click here to view Pfizer's poster, which was presented at PDA 2014, detailing their successful implementation of the Endosafe®-PTS™.

You may also be interested in…

Protecting the Horseshoe Crabs

Protecting the Horseshoe Crabs

LAL is produced using amebocytes extracted from horseshoe crab blood. Learn how we are working to protect this ancient creature.